MedTrace Logo

Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma

NCT04303897 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2024-04-12

No results posted yet for this study

Summary

Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma. Participants will be (prospective) or have already been (retrospective) implanted with XEN via specific urgent medical need.

Conditions

  • Refractory Glaucoma

Interventions

DEVICE

XEN Glaucoma Stent

Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • ALLERGAN INC. · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-19
Primary Completion
2022-03-03
Completion
2022-03-03
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04303897 on ClinicalTrials.gov